Summary of STEP results11–15
| Trial (n) | Doses and comparators | Estimated mean weight change (%) | Patients with weight loss of:>5%,>10%,>15% (%) | Body weight change from baseline (kg) |
| STEP 1 (n=1961)11 | SC semaglutide 2.4 mg | −14.9 | 86.4, 69.1, 50.5 | −15.3 |
| Placebo | −2.4 | 31.5, 12.0, 4.9 | −2.6 | |
| STEP 2 (n=1210)12 | SC semaglutide 2.4 mg | −9.6 | 68.8,45.6, 25.8 | −9.7 |
| SC semaglutide 1.0 mg | −7.0 | 57.1, 28.7, 13.7, | −2.5 | |
| Placebo | −3.4 | 28.5, 8.2, 3.2 | −1.3 | |
| STEP 3 (n=611)13 | SC semaglutide 2.4 mg | −16 | 86.6, 75.3, 55.8 | −16.8 |
| Placebo (+intensive behavioral therapy) | −5.7 | 47.6, 27, 13.2 | −6.2 | |
| STEP 4 (n=902)14 | SC semaglutide (68 total weeks) | −7.9 | NR | −7.1 |
| SC semaglutide (20 weeks), then placebo (48 weeks) | +6.9 | +6.1 | ||
| STEP 5 (n=304)15 | SC semaglutide 2.4 mg Placebo | Results pending | Results pending | Results pending |
NR means the value was not recorded in the trial results.
Results for STEP 515 are pending at the time of writing this review.
SC, subcutaneous; STEP, Semaglutide Treatment Effect in People with Obesity.